DE:UUDA Stock Latest News
Company AnnouncementsSyntara advances Parkinson’s, MDS and scar programs on solid R&D footing3d ago
Company AnnouncementsSyntara moves AGM fully online as it boosts digital engagement with investors2w ago
Company AnnouncementsSyntara Flags Risks Around Drug and Device Pipeline3w ago
Company AnnouncementsSyntara Issues New Unquoted Performance Rights Under Employee Incentive Plan4w ago- Company AnnouncementsSyntara Issues 34.9 Million Unquoted Performance Rights Under Incentive Scheme4w ago
Company AnnouncementsSyntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy1M ago
Company AnnouncementsSyntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline1M ago
Company AnnouncementsSyntara Loss Widens as Revenue Falls and Asset Base Shrinks2M ago
Company AnnouncementsSyntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar3M ago- Company AnnouncementsSyntara secures FDA backing and funding as key clinical programs advance3M ago
Company AnnouncementsSyntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder3M agoCompany AnnouncementsSyntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial4M ago
Company AnnouncementsSyntara Issues 1.75 Million Unquoted Performance Rights Under Incentive Scheme4M ago
Company AnnouncementsSyntara Limited Seeks ASX Quotation for Additional Shares4M ago
Company AnnouncementsSyntara Shifts CEO Pay Toward Long-Term Equity Incentives4M ago
Company AnnouncementsSyntara advances scar therapy trials as Phase 1b recruitment passes halfway mark4M ago
Company AnnouncementsSyntara Completes Second Tranche of A$8m Share Placement4M ago
Company AnnouncementsSyntara Wins Shareholder Backing for Capital Resolutions to Fund Drug Pipeline4M ago